Methods for measuring endocannabinoid production and expression and activity of enzymes involved in the endocannabinoid system

Lipid-Mediated Signaling

Volumn , Issue , 2010, Pages 109-148

  Bisogno, Tiziana ^a   De Petrocellis, Luciano ^b   Di Marzo, Vincenzo ^a  

^a CNR Consiglio Nazionale delle Ricerche   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957598409     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780849381423     Document Type: Chapter

References (209)

1. Gaoni, Y. and Mechoulam, R. (1971) The isolation and structure of Δ-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J. Am. Chem. Soc. 93: 217-224.
2. Howlett, A.C. et al. (2004) Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47(Suppl 1): 345-358.
3. Devane, W.A. et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258: 1946-1949.
4. Mechoulam, R. et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50: 83-90.
5. Sugiura, T. et al. (1995) 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215: 89-97.
6. Di Marzo, V. and Petrosino, S. (2007) Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol. 18: 129-140.
7. Witting, A. et al. (2004) P2X7 receptors control 2-arachidonoylglycerol production by microglial cells Proc. Natl. Acad. Sci. USA 101: 3214-3219.
8. van der Stelt, M. et al. (2005) Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J. 24: 3026-3037.
9. Jung, K.M. et al. (2005) Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol. Pharmacol. 68: 1196-1202.
10. Hashimotodani, Y. et al. (2005) Phospholipase Cbeta serves as a coincidence detector through its Ca2+ dependency for triggering retrograde endocannabinoid signal Neuron 45: 257-268.
11. Maejima, T. et al. (2005) Synaptically driven endocannabinoid release requires Ca2+-assisted metabotropic glutamate receptor subtype 1 to phospholipase Cβ4 signaling cascade in the cerebellum. J. Neurosci. 25: 6826-6835.
12. Wettschureck, N. et al. (2006) Forebrain-specific inactivation of Gq/G11 family G proteins results in age-dependent epilepsy and impaired endocannabinoid formation. Mol. Cell. Biol. 26: 5888-5894.
13. Edwards, D.A., Kim, J., and Alger, B.E. (2006) Multiple mechanisms of endocannabinoid response initiation in hippocampus. J. Neurophysiol. 95: 67-75.
14. Di Marzo, V. et al. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons Nature 372: 686-691.
15. Schmid, P.C. et al. (1983) Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type. J. Biol. Chem. 258: 9302-9306.
16. Schmid, H.H.O., Schmid, P.C., and Natarajan, V. (1990) N-Acylated glycerophospholipids and their derivatives. Prog. Lipid Res. 29: 1-43.
17. Schmid, H.H., Schmid, P.C., and Natarajan, V. (1996) The N-acylation-phosphodiesterase pathway and cell signalling Chem. Phys. Lipids 80: 133-142.
18. Hansen, H.S. et al. (1998) Formation of N-acyl-phosphatidylethanolamines and N-acetylethanolamines: Proposed role in neurotoxicity. Biochem. Pharmacol. 55: 719-725.
19. Schmid, H.H. and Berdyshev, E.V. (2002) Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: Metabolism and function Prostaglandins Leukot. Essent. Fatty Acids 66: 363-376.
20. Okamoto, Y. et al. (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 279: 5298-5305.
21. Bisogno, T. et al. (1999) Brain regional distribution of endocannabinoids: Implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun. 256: 377-380.
22. Okamoto, Y. et al. (2005) Mammalian cells stably overexpressing N-acylphosphatidylethanolamine-hydrolysing phospholipase D exhibit significantly decreased levels of N-acylphosphatidylethanolamines. Biochem. J. 389: 241-247.
23. Liu, J. et al. (2006) A biosynthetic pathway for anandamide Proc. Natl. Acad. Sci. USA 103: 13345-13350.
24. Sun, Y.X. et al. (2004) Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem. J. 380: 749-756.
25. Simon, G.M. and Cravatt, B.F. (2006) Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J. Biol. Chem. 281: 26465-26472.
26. Jin, X.H. (2007) Discovery and characterization of a Ca2+-independent phosphatidylethanolamine N-acyltransferase generating the anandamide precursor and its congeners. J. Biol. Chem. 282: 3614-3623.
27. Di Marzo, V. et al. (1996) Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells. Biochem. Biophys. Res. Commun. 227: 281-288.
28. Stella, N., Schweitze, P., and Piomelli, D. (1997) A second endogenous cannabinoid that modulates long-term potentiation Nature 388: 773-778.
29. Kondo, S. et al. (1998) 2-arachidonoylglycerol, an endogenous cannabinoid receptor agonist: Identification as one of the major species of monoacylglycerols in various rat tissues, and evidence for its generation through Ca2+-dependent and -independent mechanisms. FEBS Lett. 429: 152-156.
30. Berdyshev, E.V. et al. (2001) Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. FASEB J. 15: 2171-2178.
31. Bisogno, T. et al. (1999) Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. J. Neurochem. 72: 2113-2119.
32. Carrier, E.J. et al. (2004) Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol. Pharmacol. 65: 999-1007.
33. Oka, S. et al. (2005) Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear. J. Biol. Chem. 280: 18488-18497.
34. Bisogno, T. et al. (2003) Cloning of the first sn 1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signalling in the brain. J. Cell Biol. 163: 463-468.
35. Williams, E.J., Walsh, F.S., and Doherty, P. (2003) The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J. Cell Biol. 160: 481-486.
36. Chevaleyre, V. and Castillo, P.E. (2003) Heterosynaptic LTD of hippocampal GABAergic synapses: A novel role of endocannabinoids in regulating excitability Neuron 38: 461-472.
37. Yoshida, T. et al. (2006) Localization of diacylglycerol lipase-α around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid Cβ1 receptor. J. Neurosci. 26: 4740-4751.
38. Katona, I. et al. (2006) Molecular composition of the endocannabinoid system at glutamatergic synapses. J. Neurosci. 26: 5628-5637.
39. Brenowitz, S.D., Best, A.R., and Regehr, W.G. (2006) Sustained elevation of dendritic calcium evokes widespread endocannabinoid release and suppression of synapses onto cerebellar Purkinje cells. J. Neurosci. 26: 6841-6850.
40. McFarland, M.J. and Barker, E.L. (2004) Anandamide transport. Pharmacol. Ther. 104: 117-135.
41. De Petrocellis, L., Cascio, M.G., and Di Marzo, V. (2004) The endocannabinoid system: A general view and latest additions. Br. J. Pharmacol. 141: 765-774.
42. Ligresti, A. et al. (2004) Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochem. J. 380: 265-272.
43. Fegley, D. et al. (2004) Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172 Proc. Natl. Acad. Sci. USA 101: 8756-8761.
44. Oddi, S. et al. (2005) Confocal microscopy and biochemical analysis reveal spatial and functional separation between anandamide uptake and hydrolysis in human keratinocytes. Cell. Mol. Life Sci. 62: 386-395.
45. Moore, S.A. et al. (2005) Identification of a high-affinity binding site involved in the transport of endocannabinoids Proc. Natl. Acad. Sci. USA 102: 17852-17857.
46. Dickason-Chesterfield, A.K. et al. (2006) Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cell. Mol. Neurobiol. 26: 407-423.
47. Ortar, G. et al. (2008) Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: A critical revisitation. Eur. J. Med. Chem. 43: 62-72.
48. Kaczocha, M. et al. (2006) Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase. J. Biol. Chem. 281: 9066-9075.
49. Cravatt, B.F. et al. (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides Nature 384: 83-87.
50. Saghatelian, A. et al. (2006) A FAAH-regulated class of N-acyl taurines that activates TRP ion channels Biochemistry 45: 9007-9015.
51. Huang, S.M. et al. (2001) Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J. Biol. Chem. 276: 42639-42644.
52. Cascio, M.G. et al. (2004) A structure-activity relationship study on N-arachidonoylamino acids as possible endogenous inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. 314: 192-196.
53. McKinney, M.K. and Cravatt, B.F. (2005) Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem. 74: 411-432.
54. Puffenbarger, R.A. et al. (2001) Characterization of the 5′-sequence of the mouse fatty acid amide hydrolase. Neurosci. Lett. 314: 21-24.
55. Waleh, N.S. et al. (2002) Transcriptional regulation of the mouse fatty acid amide hydrolase gene Gene 291: 203-210.
56. Maccarrone, M. et al. (2003) Leptin activates the anandamide hydrolase promoter in human T lymphocytes through STAT3. J. Biol. Chem. 278: 13318-13324.
57. Maccarrone, M. et al. (2003) Progesterone activates fatty acid amide hydrolase (FAAH) promoter in human T lymphocytes through the transcription factor Ikaros: Evidence for a synergistic effect of leptin. J. Biol. Chem. 278: 32726-32732.
58. Kathuria, S. et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9: 76-81.
59. Lichtman, A.H. et al. (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: Evidence for an unprecedented combination of potency and selectivity. J. Pharmacol. Exp. Ther. 311: 441-448.
60. Maione, S. et al. (2007) Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br. J. Pharmacol. 150: 766-781.
61. Maccarrone, M. (2006) Fatty acid amide hydrolase: A potential target for next generation therapeutics. Curr. Pharm. Des. 12: 759-772.
62. Piomelli, D. et al. (2006) Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 12: 21-38.
63. Di Marzo, V. et al. (2007) Endocannabinoids and related compounds: Walking back and forth between plant natural products and animal physiology. Chem. Biol. 7: 741-756.
64. Flanagan, J.M. et al. (2006) The fatty acid amide hydrolase 385 A/A (P129T) variant: Haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum. Genet. 120: 581-588.
65. Sipe, J.C. et al. (2005) Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int. J. Obes. 29: 755-759.
66. Morita, Y. et al. (2005) A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia. Neurosci. Lett. 376: 182-187.
67. Wei, B.Q. et al. (2006) A second fatty acid amide hydrolase with variable distribution among placental mammals. J. Biol. Chem. 281: 36569-36578.
68. Di Marzo, V. and Deutsch, D.G. (1998) Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol. Dis. 5: 386-404.
69. Lichtman, A.H. et al. (2002) Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J. Pharmacol. Exp. Ther. 302: 73-79.
70. Di Marzo, V. et al. (1999) Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. 264: 258-267.
71. Goparaju, S.K. et al. (1999) Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem. Pharmacol. 57: 417-423.
72. Karlsson, M. et al. (2001) Exon-intron organization and chromosomal localization of the mouse monoglyceride lipase gene Gene 272: 11-18.
73. Ho, S.Y., Delgado, L., and Storch, J. (2002) Monoacylglycerol metabolism in human intestinal Caco-2 cells: Evidence for metabolic compartmentation and hydrolysis. J. Biol. Chem. 277: 1816-1823.
74. Dinh, T.P. et al. (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA 99: 10819-10824. Erratum in: Proc. Natl. Acad. Sci. USA 99: 13961.
75. Gulyas, A.I. et al. (2004) Segregation of two endocannabinoid-hydrolyzing enzymes into pre-and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur. J. Neurosci. 20: 441-458.
76. Dinh, T.P., Kathuria, S., and Piomelli, D. (2004) RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol. Pharmacol. 66: 1260-1264.
77. Muccioli, G.G. et al. (2007) Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. J. Neurosci. 11: 2883-2889.
78. Pertwee, R.G. (2006) The pharmacology of cannabinoid receptors and their ligands: An overview. Int. J. Obes. 30(Suppl 1): S13-S18; Cannabinoid pharmacology: The first 66 years. Br. J. Pharmacol. 147(Suppl 1): S163-S171.
79. Di Marzo, V. (2006) A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends Pharmacol. Sci. 27: 134-140.
80. Klein, T.W. (2005) Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 5: 400-411.
81. Maccarrone, M. (2005) The endocannabinoid system in the brain: From biology to therapy. Curr. Drug Targets CNS Neurol. Disord. 4: 613.
82. Valenti, M. et al. (2004) Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. Cell. Mol. Life Sci. 61: 945-950.
83. Di Marzo, V. et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake Nature 410: 822-825.
84. Sugiura, T., Yoshinaga, N., and Waku, K. (2001) Rapid generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in rat brain after decapitation. Neurosci. Lett. 297: 175-178.
85. Kempe, K. et al. (1996) Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue. J. Biol. Chem. 271: 17287-17295.
86. Schmid, P.C. et al. (1995) Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett. 375: 117-120.
87. Cadas, H., di Tomaso, E., and Piomelli, D. (1997) Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci. 17: 1226-1242.
88. Fontana, A. et al. (1995) Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acylethanolamines Prostaglandins Leukot. Essent. Fatty Acids 53: 301-308.
89. Koga, D. et al. (1997) Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric determination of anandamide and its analogs in rat brain and peripheral tissues. J. Chromatogr. B Biomed. Sci. Appl. 690: 7-13.
90. Kingsley, P.J. and Marnett, L.J. (2003) Analysis of endocannabinoids by Ag+ coordination tandem mass spectrometry. Anal. Biochem. 314: 8-15.
91. Richardson, D. et al. (2007) Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry. Anal. Biochem. 360: 216-226.
92. Koga, D. et al. (1995) High-performance liquid chromatography and fluorometric detection of arachidonylethanolamide (anandamide) and its analogues, derivatized with 4-(N-chloroformylmethyl-N-methyl)amino-7-N, N-dimethylaminosulphonyl-2,1,3-benzoxadiazole (DBD-COCl). Biomed. Chromatogr. 9: 56-57.
93. Sugiura, T. et al. (1996) Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Eur. J. Biochem. 240: 53-62.
94. Yagen, B. and Burstein, S. (2000) Novel and sensitive method for the detection of anandamide by the use of its dansyl derivative. J. Chromatogr. B Biomed. Sci. Appl. 740: 93-99.
95. Giuffrida, A. and Pomelli, D. (1998) Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. FEBS Lett. 422: 373-376.
96. Bisogno, T. et al. (1997) Occurrence and metabolism of anandamide and related acylethanolamides in ovaries of the sea urchin Paracentrotus lividus. Biochim. Biophys. Acta 1345: 338-348.
97. Bisogno, T. et al. (1997) Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. 272: 3315-3323.
98. Bisogno, T. et al. (1997) The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. Biochem. Biophys. Res. Commun. 239: 473-479.
99. Bisogno, T. et al. (1999) Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. Arch. Biochem. Biophys. 370: 300-307.
100. Di Marzo, V. et al. (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease. FASEB J. 10: 1432-1438.
101. Gonzales, S. et al. (1999) Identification of endocannabinoids and cannabinoid Cβ(1) receptor mRNA in the pituitary gland Neuroendocrinology 70: 137-145.
102. Di Marzo, V. et al. (2000) Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of Δ9-tetrahydrocannabinoltolerant rats. J. Neurochem. 74: 1627-1635.
103. Matias, I. et al. (2001) Evidence for an endocannabinoid system in the central nervous system of the leech Hirudo medicinalis. Brain Res. Mol. Brain Res. 87: 145-159.
104. Pinto, L. et al. (2002) Endocannabinoids as physiological regulators of colonic propulsion in mice Gastroenterology 123: 227-234.
105. Izzo, A.A. et al. (2003) An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice Gastroenterology 125: 765-774.
106. Sepe, N. et al. (1998) Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs. Possible implications for mollusc physiology and sea food industry Biochim. Biophys. Acta 1389: 101-111.
107. Izzo, A.A. et al. (2001) Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol. 134: 563-570.
108. Baker, D. et al. (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15: 300-302.
109. Lastres-Becker, I. et al. (2001) Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington’s disease Neuroreport 12: 2125-2129.
110. Yang, H.Y. et al. (1999) GC/MS analysis of anandamide and quantification of N-arachidonoylphosphatidylethanolamides in various brain regions, spinal cord, testis, and spleen of the rat. J. Neurochem. 72: 1959-1968.
111. Maccarrone, M. et al. (2001) Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. J. Neurochem. 76: 594-601.
112. Hardison, S., Weintraub, S.T., and Guiffrida, A. (2006) Quantification of endocannabinoids in rat biological samples by GC/MS: Technical and theoretical considerations. Prostaglandins Other Lipid Mediat. 81: 106-112.
113. Giuffrida, A., Rodriguez de Fonseca, F., and Piomelli, D. (2000) Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Anal. Biochem. 1: 87-93.
114. De Marchi, N. et al. (2003) Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2: 5.
115. Ligresti, A. et al. (2003) Possible endocannabinoid control of colorectal cancer growth Gastroenterology 125: 677-687.
116. Bifulco, M. et al. (2004) A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J. 18: 1606-1608.
117. van der Stelt, M. et al. (2005) A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson’s disease. FASEB J. 19: 1140-1142.
118. van der Stelt, M. et al. (2006) Endocannabinoids and β-amyloid-induced neurotoxicity in vivo: Effect of pharmacological elevation of endocannabinoid levels. Cell. Mol. Life Sci. 63: 1410-1424.
119. D’Argenio, G. et al. (2006) Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J. 20: 568-570.
120. Melis, M. et al. (2006) Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiol. Dis. 24: 15-27.
121. Mestre, J. et al. (2005) Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem. 6: 1327-1339.
122. Bisogno, T. et al. (2007) Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington’s disease. Neurochem. Int. 52: 307-313.
123. Matias, I. et al. (2006) Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 91: 3171-3180.
124. Matias, I. et al. (2006) Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration Prostaglandins Leukot. Essent. Fatty Acids 75: 413-418.
125. Cote, M. et al. (2007) Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int. J. Obes. 31: 692-699.
126. Gonthier, M.P. et al. (2007) Identification of endocannabinoids and related compounds in human fat cells Obesity 15: 837-845.
127. Karsak, M. et al. (2007) Attenuation of allergic contact dermatitis through the endocannabinoid system Science 5830: 1494-1497.
128. Huang, S.M. et al. (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors Proc. Natl. Acad. Sci. USA 99: 8400-8405.
129. Tan, B. et al. (2006) Targeted lipidomics: Discovery of new fatty acyl amides. AAPS J. 8: E461-E465.
130. Schreiber, D. et al. (2007) Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. Anal. Biochem. 2: 162-168.
131. Moesgaard, B., Jaroszewski, J.W., and Hansen, H.S. (1999) Accumulation of N-acylethanolamine phospholipids in rat brains during post-decapitative ischemia: A 31P NMR study. J. Lipid Res. 40: 515-521.
132. Moesgaard, B. et al. (2000) Age dependent accumulation of N-acyl-ethanolamine phospholipids in ischemic rat brain. A 31P NMR and enzyme activity study. J. Lipid Res. 41: 985-990.
133. Di Marzo, V. et al. (1996) Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem. J. 316: 977-984.
134. Berrendero, F. et al. (1999) Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period Synapse 33: 181-191.
135. Folch, J. et al. (1957) A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226: 497-509.
136. Peterson, G., Chapman, K.D., and Hansen, H.S. (2000) A rapid phospholipase D assay using zirconium precipitation of anionic substrate phospholipids: Application to N-acylethanolamine formation in vitro. J. Lipid Res. 41: 1532-1538.
137. Burns, D.T., Townshend, A., and Carter, A.H. (1981) Inorganic Reaction Chemistry, Vol. 2. Reactions of the Elements and Their Compounds. Ellis Horwood, New York, pp. 501-507.
138. Epps, D.E. et al. (1979) N-Acylethanolamine accumulation in infarcted myocardium. Biochem. Biophys. Res. Commun. 90: 628-633.
139. Epps, D.E. et al. (1980) Accumulation of N-acylethanolamine glycerophospholipids in infarcted myocardium Biochim. Biophys. Acta 618: 420-430.
140. Natarajan, V. et al. (1981) On the biosynthesis and metabolism of N-acylethanolamine phospholipids in infarcted dog heart Biochim. Biophys. Acta 664: 445-448.
141. Fezza, F. et al. (2005) Radiochromatographic assay of N-acyl-phosphatidylethanolaminespecific phospholipase D activity. Anal. Biochem. 339: 113-120.
142. Cadas, H. et al. (1996) Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci. 12: 3934-3942.
143. Deutsch, D.G. and Chin, S.A. (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46: 791-796.
144. Devane, W.A. and Axelrod, J. (1994) Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes Proc. Natl. Acad. Sci. USA 91: 6698-6701.
145. Desarnaud, F. et al. (1995) Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J. Biol. Chem. 11: 6030-6035.
146. Lang, W. et al. (1996) High-performance liquid chromatographic determination of anandamide amidase activity in rat brain microsomes. Anal. Biochem. 238: 40-45.
147. Maccarrone, M., Bari, M., and Finazzi Agrò, A. (1999) A sensitive and specific radiochromatographic assay of fatty acid amide hydrolase activity. Anal. Biochem. 267: 314-318.
148. Omeir, R.L. et al. (1995) Arachidonoyl ethanolamide-[1,2-14C] as a substrate for anandamide amidase. Life Sci. 56: 1999-2005.
149. Wilson, S.J., Lovenberg, T.W., and Barbier, A.J. (2003) A high-throughput-compatible assay for determining the activity of fatty acid amide hydrolase. Anal. Biochem. 318: 270-275.
150. Boldrup, L. et al. (2004) A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase J. Biochem. Biophys. Methods 60: 171-177.
151. Patterson, J.E. et al. (1996) Inhibition of oleamide hydrolase catalyzed hydrolysis of the endogenous sleep-inducing lipid cis-9-octadecenamide. J. Am. Chem. Soc. 118: 5938-5945.
152. Thumser, A.E., Voysey, J., and Wilton, D.C. (1997) A fluorescence displacement assay for the measurement of arachidonoyl ethanolamide (anandamide) and oleoyl amide (octadecenoamide) hydrolysis. Biochem. Pharmacol. 53: 433-435.
153. Patricelli, M.P. and Cravatt, B.F. (2001) Characterization and manipulation of the acyl chain selectivity of fatty acid amide hydrolase Biochemistry 40: 6107-6115.
154. DeBank, P.A., Kendall, D.A., and Alexander, S.P. (2005) A spectrophotometric assay for fatty acid amide hydrolase suitable for high-throughput screening. Biochem. Pharmacol. 69: 1187-1193.
155. Ramarao, M.K. et al. (2005) A fluorescence-based assay for fatty acid amide hydrolase compatible with high-throughput screening. Anal. Biochem. 343: 143-151.
156. Kage, K.L. (2007) A high throughput fluorescent assay for measuring the activity of fatty acid amide hydrolase J. Neurosci. Methods 161: 47-54.
157. Hasegawa-Sasaki, H. (1985) Early changes in inositol lipids and their metabolites induced by platelet-derived growth factor in quiescent Swiss mouse 3T3 cells. Biochem. J. 232: 99-109.
158. Gammon, C.M. et al. (1989) Diacylglycerol modulates action potential frequency in GH3 pituitary cells: Correlative biochemical and electrophysiological studies. Brain Res. 479: 217-224.
159. Cox, J.W. and Horrocks, L.A. (1981) Preparation of thioester substrates and development of continuous spectrophotometric assays for phospholipase A, and monoacylglycerol lipase. J. Lipid Res. 22: 496-505.
160. Strosznajder, J., Singh, H., and Horrocks, L.A. (1984) Monoacylglycerol lipase: Regulation and increased activity during hypoxia and ischemia. Neurochem. Pathol. 2: 139-147.
161. Farooqui, A.A. et al. (1984) Spectrophotometric determination of lipases, lysophospholipases, and phospholipases. J. Lipid Res. 25: 1555-1562.
162. Bisogno, T. et al. (1997) Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem. J. 322: 671-677.
163. Bisogno, T. et al. (2006) Development of the first potent and specific inhibitors of endocannabinoid biosynthesis Biochim. Biophys. Acta 1761: 205-212.
164. Rouzer, C.A., Ghebreselasie, K., and Marnett, L.J. (2002) Chemical stability of 2-arachidonylglycerol under biological conditions Chem. Phys. Lipids 119: 69-82.
165. Saario, S.M. et al. (2004) Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem. Pharmacol. 67: 1381-1387.
166. Ghafouri, N. et al. (2004) Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. Br. J. Pharmacol. 143: 774-784.
167. Tornqvist, P. et al. (1976) Purification and some properties of a monoacylglycerolhydrolysing enzyme of rat adipose tissue. J. Biol. Chem. 251: 813-819.
168. Vandevoorde, S. et al. (2005) Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. 337: 104-109.
169. Vandevoorde, S. and Fowler, C.J. (2005) Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: Evidence that VDM11 acts as an FAAH substrate. Br. J. Pharmacol. 7: 885-893.
170. Vandevoorde, S. et al. (2007) Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro. Br. J Pharmacol. 2: 186-191.
171. Laval, G. et al. (2007) Disulfiram is an inhibitor of human purified monoacylglycerol lipase, the enzyme regulating 2-arachidonoylglycerol signaling Chembiochem 11: 1293-1297.
172. Savinainen, J.R. et al. (2001) Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating Cβ(1) receptor-dependent G-protein activation in rat cerebellar membranes. Br. J. Pharmacol. 134: 664-672.
173. Saario, S.M. et al. (2005) Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. Chem. Biol. 12: 649-656.
174. Saario, S.M. et al. (2006) URB754 has no effect on the hydrolysis or signaling capacity of 2-AG in the rat brain. Chem. Biol. 8: 811-814.
175. Ueda, N., Okamoto, Y., and Morishita, J. (2005) N-acylphosphatidylethanolaminehydrolyzing phospholipase D: A novel enzyme of the β-lactamase fold family releasing anandamide and other N-acylethanolamines. Life Sci. 77: 1750-1758.
176. Tsou, K. et al. (1998) Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neurosci. Lett. 254: 137-140.
177. Van Sickle, M.D. et al. (2001) Cannabinoids inhibit emesis through Cβ1 receptors in the brainstem of the ferret Gastroenterology 121: 767-774.
178. Szabo, B. et al. (2006) Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. J. Physiol. 577: 263-280.
179. Starowicz, K.M. et al. (2008) Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet Obesity 16: 553-565.
180. Egertova, M. et al. (1998) A new perspective on cannabinoid signalling: Complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc. Biol. Sci. 265: 2081-2085.
181. Egertova, M., Cravatt, B.F., and Elphick, M.R. (2003) Comparative analysis of fatty acid amide hydrolase and Cβ(1) cannabinoid receptor expression in the mouse brain: Evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling Neuroscience 119: 481-496.
182. Egertova, M. et al. (2004) Fatty acid amide hydrolase in brain ventricular epithelium: Mutually exclusive patterns of expression in mouse and rat. J. Chem. Neuroanat. 28: 171-181.
183. Starowicz, K. et al. (2006) Endovanilloid degradative enzymes: Comparative analysis of FAAH, COMT and TRPV1 expression in the mouse brain. In 16th Annual Symposium on the Cannabinoids, Burlington, VT, International Cannabinoid Research Society, p. 114.
184. Cristino, L. et al. (2006) Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain Neuroscience 139: 1405-1415.
185. Yazulla, S. et al. (1999) Immunocytochemical localization of cannabinoid Cβ1 receptor and fatty acid amide hydrolase in rat retina. J. Comp. Neurol. 415: 80-90.
186. Glaser, S.T. et al. (2005) Endocannabinoids in the intact retina: 3 H-anandamide uptake, fatty acid amide hydrolase immunoreactivity and hydrolysis of anandamide. Vis. Neurosci. 6: 693-705.
187. Parker, R.M. and Barnes, N.M. (1999) mRNA: Detection by in situ and northern hybridization. Methods Mol. Biol. 106: 247-283.
188. Hod, Y. (1992) A simplified ribonuclease protection assay Biotechniques 13: 852-854.
189. Saccomanno, C.F. et al. (1992) A faster ribonuclease protection assay Biotechniques 13: 846-850.
190. Weis, J.H. et al. (1992) Detection of rare mRNAs via quantitative RT-PCR. Trends Genet. 8: 263-264.
191. Bucher, P. (1999) Regulatory elements and expression profiles. Curr. Opin. Struct. Biol. 9: 400-407.
192. Melton, D.A. et al. (1984) Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucleic Acids Res. 12: 7035-7056.
193. Morrison, T.B., Weis, J.J., and Wittwer, C.T. (1998) Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification Biotechniques 24: 954-962.
194. Karge, W.H., III, Schaefer, E.J., and Ordovas, J.M. (1998) Quantification of mRNA by polymerase chain reaction (PCR) using an internal standard and a nonradioactive detection method. Methods Mol. Biol. 110: 43-61.
195. Bustin, S.A. (2002) Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): Trends and problems. J. Mol. Endocrinol. 29: 23-39.
196. Curtiss, N.P. et al. (2005) Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22 Genomics 85: 600-607.
197. Spoto, B. et al. (2006) Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol Biochimie 88: 1889-1897.
198. Guo, Y. et al. (2005) N-acylphosphatidylethanolamine-hydrolyzing phospholipase D is an important determinant of uterine anandamide levels during implantation. J. Biol. Chem. 280: 23429-23432.
199. Morishita, J. et al. (2005) Regional distribution and age-dependent expression of N-acylphosphatidylethanolamine-hydrolyzing phospholipase D in rat brain. J. Neurochem. 94: 753-762.
200. Hansson, A.C. et al. (2007) Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference Neuropsychopharmacology 32: 117-126.
201. Strausberg, R.L. et al. (2002) Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences Proc. Natl. Acad. Sci. USA 99: 16899-16903.
202. Gjerstorff, M.F. et al. (2006) Identification of genes with altered expression in medullary breast cancer vs. ductal breast cancer and normal breast epithelia. Int. J. Oncol. 28: 1327-1335.
203. Jung, K.M. et al. (2007) A key role for diacylglycerol lipase-α in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Mol. Pharmacol. 72: 612-621.
204. Giang, D.K. and Cravatt, B.F. (1997) Molecular characterization of human and mouse fatty acid amide hydrolases Proc. Natl. Acad. Sci. USA 94: 2238-2242.
205. Helliwell, R.J. et al. (2004) Characterization of the endocannabinoid system in early human pregnancy. J. Clin. Endocrinol. Metab. 89: 5168-5174.
206. Engeli, S. et al. (2005) Activation of the peripheral endocannabinoid system in human obesity Diabetes 54: 2838-2843.
207. Bluher, M. et al. (2006) Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity Diabetes 55: 3053-3060.
208. Tanaka, M. et al. (2007) The mRNA expression of fatty acid amide hydrolase in human whole blood correlates with sepsis. J. Endotoxin Res. 13: 35-38.
209. Siegmund, S.V. et al. (2006) Fatty acid amide hydrolase determines anandamideinduced cell death in the liver. J. Biol. Chem. 281: 10431-10438.